跳至主要内容
临床试验/NL-OMON55412
NL-OMON55412已完成4 期

Highlow study: Low-molecular-weight heparin to prevent recurrent VTE in pregnancy: a randomized controlled trial of two doses - Highlow

Academisch Medisch Centrum0 个研究点目标入组 200 人开始时间: 待定最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • - Age >= 18 years
  • - Pregnancy confirmed by urinary pregnancy test, gestational age < 14 weeks
  • since first day of last menstrual period
  • - Previous objectively confirmed VTE, either unprovoked, in the presence of use
  • of oral contraceptives or estrogen/progestagen use, or related to pregnancy or
  • the postpartum period, or minor risk factors (e.g. long distance travel, minor

排除标准

  • - Previous VTE related to a major provoking risk factor (e.g. surgery, major
  • trauma or plaster cast immobilisation in the 3 months prior to VTE) as the sole
  • risk factor
  • - Indication for treatment with therapeutic dose anticoagulant therapy (e.g.
  • treatment of acute VTE; permanent use of therapeutic anticoagulants outside of
  • - Inability to provide informed consent
  • - Any contraindication listed in the local labelling of LMWH.

研究者

相似试验